Matilde Lleonart Pajarin I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London. Instituciones de las que forman parte Jefe de grupo Cáncer de cabeza y cuello: Investigación biomédica en células madre tumorales Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Matilde Lleonart Pajarin LinkedIn Twitter Orcid Email Instituciones de las que forman parte Jefe de grupo Cáncer de cabeza y cuello: Investigación biomédica en células madre tumorales Vall Hebron Institut de Recerca I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.
My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group. Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis. Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models. In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.
Líneas de investigación Study of new genes involved in proliferation Searching for new proliferative genes/tumor suppressor genes is being performed at our laboratory by carring out genetic screens. By the use of retroviral vectors as carriers of a cDNA libraries (formed by mRNA from murine embryonic stem cells), primary cells are infected and screening for those clones able to bypass senescence are selected for further characterization. The marked morphological heterogeneity observed in several tumorigenic process, support the hypothesis that several cancers have their origin in a stem cell. It is believed that genes expressed by embryonic stem cells, may play an important role in the tumorigenic mechanism.This project unravels the effect of immortal genes existing in embryonic stem cells, when are forced to be expressed in primary and thereby mortal cells. These immortal genes are future candidate markers in tumors with potential prognosis value. The novel genes discovered, are being analyzed in the biopsies from patients with different kinds of tumors collected at the Pathology Department of the Vall d´Hebrón Hospital. IP: Matilde Lleonart Pajarin Paginación Primera página « Página anterior ‹ Página 1 Página actual 2 Proyectos Ayudas Margarita Salas IP: Matilde Lleonart Pajarin Colaboradores: Yoelsis Garcia Mayea, Judit Álvarez González Entidad financiadora: Ministerio de Universidades Financiación: 0.01 Referencia: MIU/M_SALAS/2021/GARCIA_UB Duración: 01/04/2022 - 31/03/2022 Novel terapéutic approaches against COVID-19 IP: Matilde Lleonart Pajarin Colaboradores: Marina Bataller Fernández, Almudena Sanchez Garcia, Yoelsis Garcia Mayea Entidad financiadora: Fundació La Marató de TV3 Financiación: 161875 Referencia: 202116 Duración: 23/09/2021 - 22/09/2024 New therapeutic approaches in head and neck cancer IP: Matilde Lleonart Pajarin Colaboradores: Yoelsis Garcia Mayea, Jordi Temprana Salvador, Angel García Jiménez, Josep Castellví Vives, Laia Josa Culleré, Marina Bataller Fernández Entidad financiadora: Instituto de Salud Carlos III Financiación: 183920 Referencia: PI20/00556 Duración: 01/01/2021 - 30/06/2025 Drug-screen against novel proteins involved in cancer resistance IP: Matilde Lleonart Pajarin Colaboradores: Almudena Sanchez Garcia, Miriam Izquierdo Sans Entidad financiadora: Fundació Institut de Recerca HUVH Financiación: 50649.27 Referencia: VHIR/BEQUESPREDOC/2019/SANCHEZ Duración: 14/09/2020 - 13/09/2023 Paginación Primera página « Página anterior ‹ Página 1 Página actual 2 Página 3 Página 4 Página 5 … Siguiente página › Última página »
